Affymax folds after drug withdrawal


Biotech firm Affymax is to be dissolved after post-marketing reports of serious hypersensitivity reactions prompted it to recall its anaemia drug Omontys (peginesatide).

An investigation in conjunction with its marketing partner Takeda found no quality or manufacturing issues with Omontys. However, it also failed to identify any specific root cause for the allergic reactions, so the companies were left with no option but to withdraw the product. Takeda has broken off its marketing agreement with Affymax, effective from 10 September and, subject to shareholder approval, the company will be liquidated .

Omontys is a PEGylated peptide drug used to treat anaemia caused by chronic kidney disease.


Related Content

Chemistry's grand challenges

28 August 2013 Premium contentFeature

news image

What are the big problems for the next generation of chemists to work on? Mark Peplow takes up the gauntlet

Anarchy in the proteome

29 July 2011 Premium contentFeature

news image

15 years ago, the idea that proteins might be functional without a well-ordered 3D structure was heretical. But Michael Gross...

Most Read

Perovskite solar cells show hydrogen production promise

26 September 2014 Research

news image

Highly efficient solar cells and catalysts made from cheap, common materials use sunlight to split water

Big name coffee chains drawn into acrylamide fight

23 September 2014 News and Analysis

news image

Starbucks and other coffee chains are being sued in California by a non-profit that wants carcinogen labels slapped on their ...

Most Commented

Perovskite solar cells show hydrogen production promise

26 September 2014 Research

news image

Highly efficient solar cells and catalysts made from cheap, common materials use sunlight to split water

First interstellar sighting of a branched alkyl molecule

25 September 2014 Research

news image

Discovery shows that stellar nurseries could hold amino acids too that might have been the spark for life on Earth